## ACLS: Axcelis Technologies, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%); PEG 1.23 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($81.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Axcelis Technologies' (NASDAQ:ACLS) investors will be pleased with their stellar 212% return over the last five years**
- Source: Yahoo Finance | 20251211T110941 | Bullish | Relevance: 98%
-  Axcelis Technologies (NASDAQ:ACLS) has delivered a stellar 212% return to investors over the past five years, reflecting strong growth in its share price. The company's earnings per share (EPS) have also grown at an impressive 26% annually over the same period, indicating that investor sentiment aligns well with the business's underlying performance. This consistent growth suggests stability and a positive outlook for shareholders.

**2. Axcelis to Showcase Advanced Ion Implant Solutions at SEMICON Japan 2025**
- Source: PR Newswire Asia | 20251209T230201 | Bullish | Relevance: 97%
-  Axcelis Technologies, Inc. (Nasdaq: ACLS) announced its participation in SEMICON Japan 2025, where it will showcase its advanced ion implant technologies from December 17-19 in Tokyo. The company plans to feature its Purion Power Series+™, Purion H™ Series, Purion XE™ Series, and GSD Ovation™ ES systems. Dr. Russell Low, President and CEO of Axcelis, highlighted the company's commitment to Japan's semiconductor manufacturers and its expanding support infrastructure in the region.

**3. Axcelis to Showcase Advanced Ion Implant Solutions at SEMICON Japan 2025**
- Source: PR Newswire | 20251210T130913 | Bullish | Relevance: 97%
-  Axcelis Technologies, Inc. will participate in SEMICON Japan 2025 to showcase its advanced ion implant solutions. The company will feature its Purion Power Series+, Purion H™ Series, Purion XE™ Series, and GSD Ovation™ ES systems, designed to boost device performance, enhance productivity, and reduce cost of ownership for semiconductor manufacturers. Axcelis President and CEO Dr. Russell Low highlights the company's commitment to delivering innovative solutions and support to its growing customer base in Japan.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 15.7% (-3.1%)
- Vanguard Group Inc: 13.5% (-3.2%)
- Reinhart Partners, L: 5.2% (+6.0%)
- American Century Com: 4.3% (-18.9%)
- State Street Corpora: 4.0% (-1.5%)

### Key Risks

1. High short interest (19.3%, 6.4 days to cover): squeeze risk or crowded bearish bet.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.23 suggests fair value with growth premium. Forward P/E 19.5x stretched relative to 2% growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (5.0x), low leverage (D/E 0.33). Institutional flow bearish (5 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 1.72 |
| 52W Range | $40.40 - $102.93 |
| Short Interest | 19.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.23 |
| Forward P/E | 19.5 |
| Current P/E | 20.0 |
| YoY Growth | 2.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 7.0% to 1.5% (-5.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.00), confirming momentum. RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.50% (CS: 55) | Neutral |
| RSI_14 | 58.6 | Neutral |
| MACD Histogram | 1.00 | Bullish |
| vs SMA20 | 1.067x | Above |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.248x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $89.08
- **Stop Loss:** $81.90 (8.1% risk)
- **Target:** $96.26 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 192
- **Position Value:** $17,103.36
- **Portfolio %:** 17.10%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-09 (Est: $1.12)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.00 | $1.21 | +20.6% |
| 2025Q2 | $0.71 | $1.13 | +59.2% |
| 2025Q1 | $0.38 | $1.04 | +171.3% |
| 2024Q4 | $1.25 | $1.54 | +23.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*